Sergio Cifuentes/X
Apr 7, 2025, 08:34
Sergio Cifuentes Canaval: Extended Reduced-Dose Apixaban for Cancer-Associated VTE
Sergio Cifuentes Canaval, Cancer Research Project Manager at CENEIT México, posted on X:
“API-CAT Study: Extended Reduced-Dose Apixaban for Cancer-Associated VTE
- Apixaban 2.5 mg vs 5.0 mg twice daily for 12m
- Med treat.: 11.8m
- Rec VTE: 2.1% (2.5) vs 2.8% (5.0)
- Bleeding: 12.1% vs 15.6%
- Mortality: 17.7% vs 19.6%.”
“Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism.”
Authors: Isabelle Mahé et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 7, 2025, 05:32
Apr 7, 2025, 03:43
Apr 7, 2025, 02:45